|
AVRO | Tectonic Therapeutic, Inc. |
|
|
AVRO | Tectonic Therapeutic, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 11.75 |
| Leverage | 4.63% |
| Market Cap | $ 62.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -83.3m |
| Margin | 41657.19% |
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases after a single dose worldwide. The company is headquartered in Cambridge, Massachusetts.